- -

The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients

RiuNet: Repositorio Institucional de la Universidad Politécnica de Valencia

Compartir/Enviar a

Citas

Estadísticas

  • Estadisticas de Uso

The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients

Mostrar el registro completo del ítem

Camps, C.; Jantus Lewintre, E.; Cabrera, A.; Blasco, A.; Sanmartin, E.; Gallach, S.; Caballero, C.... (2011). The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients. Lung Cancer. 72(3):365-369. https://doi.org/10.1016/j.lungcan.2010.09.005

Por favor, use este identificador para citar o enlazar este ítem: http://hdl.handle.net/10251/77414

Ficheros en el ítem

Metadatos del ítem

Título: The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients
Autor: Camps, Carlos Jantus Lewintre, Eloisa Cabrera, Andrea Blasco, Ana Sanmartin, Elena Gallach, Sandra Caballero, Cristina del Pozo, Nieves Rosell, Rafael Guijarro, Ricardo Sirera Pérez, Rafael
Entidad UPV: Universitat Politècnica de València. Escuela Técnica Superior de Ingeniería Agronómica y del Medio Natural - Escola Tècnica Superior d'Enginyeria Agronòmica i del Medi Natural
Fecha difusión:
Resumen:
Qualitative analysis of circulating DNA in the blood is a promising non-invasive diagnostic and prognostic tool. Our aim was to study the association between the presence of KRAS mutations at codon 12 and several clinical ...[+]
Palabras clave: KRAS , Molecular markers , Non-small cell lung cancer (NSCLC) , Prognostic factors , Cisplatin , DNA , Docetaxel , Adult , Advanced cancer , Aged , Allele , Article , Blood sampling , Cancer chemotherapy , Cancer patient , Cancer staging , Cancer survival , Codon , Disease course , DNA extraction , Female , Gene mutation , Genetic association , Histopathology , Human , Lung adenocarcinoma , Lung non small cell cancer , Lung squamous cell carcinoma , Major clinical study , Male , Multiple cycle treatment , Oncogene K ras , Overall survival , Plasma , Priority journal , Prognosis , Progression free survival , Reverse transcription polymerase chain reaction , Wild type , Carcinoma, Non-Small-Cell Lung , Disease Progression , DNA Mutational Analysis , Follow-Up Studies , Genetic Association Studies , Humans , Lung Neoplasms , Middle Aged , Mutation , Neoplasm Staging , Predictive Value of Tests , Proto-Oncogene Proteins , Ras Proteins , Survival Analysis
Derechos de uso: Cerrado
Fuente:
Lung Cancer. (issn: 0169-5002 )
DOI: 10.1016/j.lungcan.2010.09.005
Editorial:
Elsevier
Versión del editor: https://dx.doi.org/10.1016/j.lungcan.2010.09.005
Código del Proyecto:
info:eu-repo/grantAgreement/MSC//RD06%2F0020%2F1024/ES/RED TEMÁTICA DE INVESTIGACIÓN COOPERATIVA DEL CANCER/
Agradecimientos:
This work was sponsored in part by a grant from the Spanish Society of Medical Oncology (SEOM) and by a grant (RD06/0020/1024) from Red Tematica de Investigacion Cooperativa en Cancer (RTICC), Instituto de Salud Carlos III ...[+]
Tipo: Artículo

recommendations

 

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro completo del ítem